Applied therapeutics announces multiple data presentations at the american heart association scientific sessions november 5-7, 2022

New york, oct. 31, 2022 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced multiple data presentations at the upcoming american heart association scientific sessions, to be held november 5-7, 2022 in chicago, il. data to be presented includes mechanistic support for at-001 in a diabetic cardiomyopathy mouse model, demonstrating that at-001 treatment prevents fibrosis and adverse cardiac remodeling; baseline data from the ongoing phase 3 arise-hf study on quality of life impact of disease and correlation of cardiac functional capacity (peak vo2) with physical function; additional dbcm diagnosis and prevalence data.
APLT Ratings Summary
APLT Quant Ranking